Biogen Idec Inc. (BIIB) Submits Application For Approval Of Fampridine-PR Tablets In Europe
January 12, 2010 11:28 AM
Biogen Idec Inc. (NASDAQ: BIIB) has announced submission of a marketing authorization application (MAA) to the European Medicines Agency for its Fampridine Prolonged Release tablets. The oral therapy improves walking ability in adult patients with multiple sclerosis.
Biogen Idec Inc. has also filed a New Drug Submission (NDS) with Health Canada. Biogen Idec’s Chief Executive Officer James C. Mullen will also present to investors Biogen’s plan to continue to drive shareholder value at the 28th Annual JPMorgan (NYSE: JPM) Healthcare conference in San Francisco today.
Mr. Mullen who retires from his post as Chief Executive effective June 8, 2010, said that Biogen Idec has a strong platform of products, pipeline and financial position to deliver shareholder value.
